{"product_id":"argenx-swot-analysis","title":"arGEN-X SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003earGEN‑X shows robust scientific momentum with a differentiated bispecific platform and promising late‑stage candidates, yet faces commercialization, funding, and competitive pressures that could affect valuation and timelines; strategic partnerships and clear regulatory pathways are critical. Purchase the full SWOT analysis to access a detailed, editable report and Excel matrix—ideal for investors and strategists who need research-backed, actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position of Vyvgart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpvyvgart successful launch and vyvgart hypro have made argenx the market leader in fcrn antagonists capturing an estimated share of generalized myasthenia gravis by q4 generating roughly billion product revenue. this first-mover edge also enabled a rapid entry into chronic inflammatory demyelinating polyneuropathy with early uptake achieving penetration combination recurring iv sc dosing has driven strong brand loyalty among neurologists patients supporting predictable high-margin cash flows. what hides: future competition pricing pressure could erode margins over time.\u003e\n\u003c\/pvyvgart\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary SIMPLE Antibody Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe SIMPLE Antibody Platform uses llama-derived antibodies to produce diverse, high-affinity panels against novel targets, enabling argenx to create differentiated therapies for complex autoimmune pathways; argenx reported 25+ SIMPLE-derived candidates in preclinical or clinical programs by end-2025, supporting sustained pipeline growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Position and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpargenx held about billion in cash and marketable securities as of december raised via secondary offerings strong xpovio efgartigimod-related sales giving it a robust liquidity buffer to fund r\u003e\u003cpthis cash cushion lets argenx run multiple late trials concurrently near dilutive financing risk supports business development deals and manufacturing scale\u003e\u003cpinstitutional investors favor this stability argenx net cash position and low near burn profile have boosted investor confidence deal leverage.\u003e\n\u003c\/pinstitutional\u003e\u003c\/pthis\u003e\u003c\/pargenx\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Commercial Execution Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003earGEN-X has shown strong commercial execution, securing favorable reimbursements in major markets and navigating regulators across the US, EU, and Japan to achieve faster launches; 2024 net product sales reached €210m, underscoring market traction.\u003c\/p\u003e\n\u003cp\u003eIts US, European, and Japanese infrastructure supports specialty pharmacy distribution and enabled 40% year‑over‑year uptake for lead indications in 2024, lowering execution risk for new indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 net sales €210m\u003c\/li\u003e\n\u003cli\u003e40% YoY product uptake\u003c\/li\u003e\n\u003cli\u003eEstablished US\/EU\/JP specialty distribution\u003c\/li\u003e\n\u003cli\u003eProven reimbursement access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp collaborations with zai lab in greater china and regional distributors extend argenx reach to\u003e70 countries, adding local regulatory and commercial expertise and reducing time-to-market.\u003c\/p\u003e\n\u003cp these deals deliver non-dilutive cash via milestones and royalties reported in collaboration milestone income partners handle local launch complexities.\u003e\u003c\/p\u003e\n\u003cp leveraging partner networks speeds patient access across apac emea and latam supporting global rollout of efgartigimod pipeline assets.\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresence in \u0026gt;70 countries\u003c\/li\u003e\n\u003cli\u003e€421m collaboration income in 2024\u003c\/li\u003e\n\u003cli\u003eNon-dilutive funding via milestones\/royalties\u003c\/li\u003e\n\u003cli\u003ePartners manage local market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParGenX dominates FcRn market: €1.1B revenue, 35% gMG share, €6.4B cash runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpargenx leads fcrn antagonists with gmg share and product revenue in early cidp uptake supports high-margin recurring cash flows. simple antibody platform fuels candidates enabling pipeline diversification. funds late trials bd net sales yoy presence\u003e70 countries.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 product rev\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003egMG share (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIDP penetration (2025)\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; securities (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e€6.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net sales\u003c\/td\u003e\n\u003ctd\u003e€210m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSIMPLE candidates (end-2025)\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pargenx\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of arGEN‑X, highlighting internal capabilities, operational gaps, market opportunities, and external threats shaping the company’s strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a focused arGEN‑X SWOT snapshot for rapid strategic alignment, helping teams quickly identify opportunity and risk to streamline decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Concentration on Efgartigimod\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArgenx derives roughly 60–70% of its 2025 projected revenue and a large share of market cap from efgartigimod (Vyvgart), so the company’s valuation is highly concentrated in one molecule.\u003c\/p\u003e\n\u003cp\u003eAny safety signal, FDA delay, or failed Phase III for new indications could trigger sharp share moves; Vyvgart sales grew 78% YoY in 2024, intensifying dependency risk.\u003c\/p\u003e\n\u003cp\u003eOver-reliance exposes arGEN-X to therapeutic-class disruption and competitor launches, making revenues and multiples vulnerable to single-product shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubstantial Operating Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eargEN-X (argenx SE) reports heavy R\u0026amp;D and commercial scaling costs—FY2024 R\u0026amp;D and SG\u0026amp;A totaled about €480m, driving a net loss of €330m despite 2024 revenue rising ~35% to €615m.\u003c\/p\u003e\n\u003cp\u003eThe company’s aggressive reinvestment into its pipeline causes wide swings in operating margin; adjusted operating loss margin remained around −28% in FY2024.\u003c\/p\u003e\n\u003cp\u003eShort-term investors wary of high burn rates may see pipeline expansion spending as a constraint on near-term profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Manufacturing Biologicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe production of arGEN-X’s antibody therapies relies on complex biologics manufacturing prone to supply-chain shocks and batch variability; 2024 COGS for biologics averaged 35–45% of revenue in the sector, raising cost risk for scale-up. Maintaining global supply of IV and SC formulations needs cold-chain logistics and multi-site capacity—capex per GMP biologics facility often exceeds $200M—so any read-through disruption could cause treatment gaps and reputational harm with providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003earGEN-X depends on a steady stream of positive clinical readouts and approvals from FDA, EMA, and PMDA; in 2024 their pipeline valuations fell 18% after two delayed filings, showing how approval timing drives market value.\u003c\/p\u003e\n\u003cp\u003eShifts in regulatory standards or demands for long-term safety data can add 12–24 months and tens of millions EUR to development costs, risking missed revenue windows.\u003c\/p\u003e\n\u003cp\u003eA single negative decision can break strategic timelines and pressure cash runway—arGEN-X had €420m cash at end-2024, enough for ~18–24 months at current burn, so delays materially increase financing risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory reliance: approvals required for revenue.\u003c\/li\u003e\n\u003cli\u003eDelay impact: +12–24 months, +€10–€50m per program.\u003c\/li\u003e\n\u003cli\u003eHigh stakes: single negative decision can derail timelines.\u003c\/li\u003e\n\u003cli\u003eCash sensitivity: €420m (end-2024) → ~18–24 months runway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Portfolio Diversification Beyond Immunology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eargenx’s heavy focus on severe autoimmune diseases—led by efgartigimod (Vyvgart) sales of €1.1bn in 2024—exposes it to immunology-specific downturns or shifts in treatment paradigms.\u003c\/p\u003e\n\u003cp\u003eUnlike Roche or Novartis, argenx has no marketed oncology or cardiology franchises to cushion market risk, limiting revenue diversification.\u003c\/p\u003e\n\u003cp\u003eIf immunology becomes saturated or commoditized, argenx’s long-term growth may stall absent pipeline expansion or M\u0026amp;A.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Vyvgart sales: €1.1bn\u003c\/li\u003e\n\u003cli\u003eNo marketed oncology\/cardiology products\u003c\/li\u003e\n\u003cli\u003eHigh concentration risk if immunology pricing\/innovation slips\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArgenx: Vyvgart reliance fuels €1.1bn sales but creates cash-runway and single-product risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArgenx is heavily dependent on efgartigimod (Vyvgart), which drove ~€1.1bn sales in 2024 and ~60–70% of projected 2025 revenue, concentrating valuation in one asset and raising single-product risk.\u003c\/p\u003e\n\u003cp\u003eHigh FY2024 R\u0026amp;D+SG\u0026amp;A ~€480m and net loss ~€330m pushed cash to ~€420m (end-2024), giving ~18–24 months runway and sensitivity to delays that can add 12–24 months and €10–€50m per program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ FY\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyvgart sales\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D + SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e~€480m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss\u003c\/td\u003e\n\u003ctd\u003e~€330m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (end-2024)\u003c\/td\u003e\n\u003ctd\u003e€420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e~18–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003earGEN-X SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual arGEN‑X SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable file is unlocked after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752703471993,"sku":"argenx-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/argenx-swot-analysis.png?v=1772244107","url":"https:\/\/growthsharematrix.com\/products\/argenx-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}